首页> 外文期刊>Drug and alcohol review >Attitudes in Australia on the upscheduling of over‐the‐counter codeine to a prescription‐only medication
【24h】

Attitudes in Australia on the upscheduling of over‐the‐counter codeine to a prescription‐only medication

机译:在澳大利亚态度对仅对处方药药物的过度计数次数

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Introduction and Aims. In December 2016, the Australian Therapeutic Goods Administration announced that over‐the‐counter (OTC) codeine would be available by prescription‐only in February 2018. Prior to this announcement, the authors aimed to evaluate attitudes among Australian codeine consumers, pharmacists and general medical practitioners (GP) towards the proposed upscheduling of OTC codeine. Design and Methods. Public Therapeutic Goods Administration submissions on codeine upscheduling were assessed, and a brief questionnaire was developed to assess the common issues raised. Participants (354 codeine consumers; 220 pharmacists; 120 GPs) completed a web‐based questionnaire. Comparisons of attitudes on specific statements related to codeine upscheduling were made between consumers who were in support and those who opposed the proposal and between pharmacists and GPs. Regression models were conducted to examine correlates of attitudes towards codeine restriction. Results. Most consumer, pharmacist and a third of GP respondents opposed the upscheduling of codeine. Consumers, on average, questioned whether the proposed intervention would address the intended targets of minimising codeine‐related side effects and risk of codeine dependence. Like consumers, pharmacists indicated concern around whether codeine restriction would address concerns of associated harm and dependence, as well as the burden regular GP appointments would create in terms of finances for consumers and time for GPs. GPs themselves, did not support these views. Discussion and Conclusions. Consumer responses identify key targets for educational campaigns when codeine is rescheduled, particularly around effective alternatives to OTC codeine. Additionally, contrasting views of pharmacists and GPs reinforce the importance of pharmacovigilance in evaluating the effectiveness of codeine restriction, once implemented. [McCoy J, Bruno R, Nielsen S. Attitudes in Australia on the upscheduling of over‐the‐counter codeine to a prescription‐only medication. Drug Alcohol Rev 2017;00:000‐000]
机译:摘要介绍和目标。 2016年12月,澳大利亚治疗机构政府宣布,柜台上的(OTC)可待因将通过免税2018年2月提供。在本公告之前,作者旨在评估澳大利亚可待因消费者,药剂师和将军的态度医学从业者(GP)向建议的OTC准确升起。设计和方法。公共治疗货物管理局评估了可待因上升的陈述,并制定了一个简短的问卷来评估提出的常见问题。参与者(354个可待因的消费者; 220个药剂师; 120 GPS)完成了基于网络的问卷。在支持的消费者和反对提案和药剂师和GPS之间的消费者之间进行了与可待因上升相关的具体陈述的态度比较。进行回归模型以检查对可待因限制的态度相关性。结果。大多数消费者,药剂师和三分之一的GP受访者反对可待因的上升。平均而言,消费者质疑拟议的干预是否会解决最大限度地减少与可待因相关的副作用和可待因依赖风险的预期目标。像消费者一样,药剂师围绕无论是可待因的限制是否会解决相关危害和依赖的疑虑,以及常规GP约会的负担将在消费者和GPS时间的资金方面创造。 GPS本身,不支持这些观点。讨论和结论。消费者响应在补习被重新安排时识别教育活动的关键目标,特别是围绕OTC疑问的有效替代方案。此外,药剂师和GPS的对比视图加强了药物检测的重要性,曾经实施过的评估可待因限制的有效性。 [McCoy J,Bruno R,Nielsen S.澳大利亚的态度在澳大利亚对处方药物的过度计数次数。药物酒精Rev 2017; 00:000-000]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号